Wanbury Limited

Healthcare · Pharmaceuticals & Biotechnology

NSE: WANBURY BSE: 524212

₹199.50

Sept. 30, 2026 · NSE · nse_bhavcopy

Peers in Pharmaceuticals & Biotechnology

The largest companies in the same industry by market cap. This company ranks #99 of 184. PE, ROE, 1Y return and scores come from the daily/weekly precomputed snapshot.

Company	Market cap (₹ Cr)	PE (TTM)	ROE	1Y return	Div. yield	Quality	Valuation	Momentum
Sun Pharmaceutical Industries Limited	435,863	146.5	13.7%	11.0%	—	72	8	30
Divi's Laboratories Limited	246,660	83.9	15.3%	62.7%	0.32%	70	4	51
Torrent Pharmaceuticals Limited	162,454	78.2	12.2%	34.6%	0.79%	56	0	31
Zydus Lifesciences Limited	115,910	33.3	17.3%	17.2%	0.09%	74	24	84
Cipla Limited	108,736	35.4	11.2%	-11.0%	0.97%	73	29	62
Laurus Labs Limited	106,969	122.5	17.1%	127.1%	—	78	24	53
Mankind Pharma Limited	103,406	47.4	11.7%	2.6%	—	68	12	86
Dr. Reddy's Laboratories Limited	102,916	154.7	10.9%	-0.9%	—	62	33	71
Wanbury Limited (this stock)	697	11.5	26.6%	-20.0%	—	44	65	25

Valuation multiples

Current only. Market cap is the whole company's; sales/EBITDA are trailing-twelve-month standalone; debt and cash come from the latest filed standalone balance sheet (March 31, 2026). EBITDA = PBT + interest + depreciation.

Enterprise value

₹911 Cr

EV / EBITDA

9.5x

EV / Sales

1.40x

Market cap / Sales

1.07x

Earnings yield

8.70%

Quarterly Financials

Download CSV

Standalone Consolidated

↑ Positive

Quarterly Revenue

Jun 2026 quarterly revenue is Rs 166 Cr, up 1.5% YoY.

↓ Negative

Quarterly Net Profit

Jun 2026 quarterly net profit is Rs 3 Cr, down 76.0% YoY.

Period end	Revenue (₹ Cr)	PBT (₹ Cr)	Net profit (₹ Cr)	Basic EPS
June 30, 2026	166	5	3	₹0.9300
March 31, 2026	165	15	22	₹7.3300
Dec. 31, 2025	162	16	16	₹4.5200
Sept. 30, 2025	160	15	15	₹4.5800
June 30, 2025	163	14	13	₹4.1200
March 31, 2025	172	19	20	₹6.1800
Dec. 31, 2024	133	1	1	₹0.3800
Sept. 30, 2024	161	8	8	₹2.4400
June 30, 2024	131	1	1	₹0.3200
March 31, 2024	139	8	8	₹2.4700
Dec. 31, 2023	145	10	10	₹3.1400
Sept. 30, 2023	144	7	7	₹2.2500
June 30, 2023	146	5	5	₹1.4300

Quarterly income statement (standalone, ₹ Cr)

Indicator	Jun 26	Mar 26	Dec 25	Sep 25	Jun 25	Mar 25	Dec 24	Sep 24	Jun 24	Mar 24	Dec 23	Sep 23	Jun 23
Total income (before exceptional items)	166	165	163	160	164	174	134	163	132	140	146	145	147
Operating revenue	166	165	162	160	163	172	133	161	131	139	145	144	146
Other income	0	0	0	0	0	2	1	2	1	1	1	1	1
Operating expenses	149	135	136	134	139	142	120	141	120	121	124	127	133
Operating profit	16	30	27	26	24	30	14	20	11	18	21	17	13
Operating profit margin	9.8%	18.1%	16.4%	16.1%	15.0%	17.2%	10.4%	12.4%	8.4%	13.0%	14.5%	12.0%	9.1%
Depreciation	4	3	4	4	4	3	3	3	3	3	3	3	3
Interest	8	8	7	7	8	9	10	10	8	7	8	8	6
Exceptional items, gain / (loss)	—	-4	—	—	—	—	—	—	—	—	—	—	—
Profit before tax	5	15	16	15	14	19	1	8	1	8	10	7	5
Tax	1	-7	0	-0	0	-1	0	0	—	0	-0	-0	0
Net profit	3	—	16	—	13	—	1	8	1	8	10	7	5
EPS	0.93	7.33	4.52	4.58	4.12	6.18	0.38	2.44	0.32	2.47	3.14	2.25	1.43
Net profit (TTM)	—	—	—	—	—	—	18	27	27	30	23	10	2
EPS (TTM)	17.36	20.55	19.40	15.26	13.12	9.32	5.61	8.37	8.18	9.29	7.31	3.17	0.65

Total income excludes exceptional items, which are shown on their own row. Trendlyne and Screener fold exceptional items into revenue or other income, so their totals differ from this table by exactly that row.

Annual Financials

Year ended	Revenue (₹ Cr)	PBT (₹ Cr)	Net profit (₹ Cr)
March 31, 2026	650	60	66
March 31, 2025	600	30	31
March 31, 2024	576	31	30
March 31, 2023	500	-10	-10

Annual income statement (standalone, ₹ Cr; CAGR to the latest year)

Indicator	CAGR 3Y	CAGR 5Y	Mar 26	Mar 25	Mar 24	Mar 23	Mar 22	Mar 21	Mar 20	Mar 19	Mar 18	Mar 17
Total income (before exceptional items)	9.2%	10.5%	651^†	605^†	579^†	501^†	513^†	395^†	369^†	401^†	450^†	444^†
Operating revenue	9.2%	10.6%	650	600	576	500	511^†	393^†	367^†	391^†	374^†	437^†
Other income	—	—	1^†	5^†	3^†	1^†	2^†	2^†	1^†	9^†	76^†	8^†
Operating expenses	—	—	544^†	523^†	506^†	476^†	476^†	374^†	344^†	376^†	442^†	402^†
Operating profit	66.4%	42.7%	107^†	76^†	70^†	23^†	35^†	18^†	23^†	15^†	-67^†	34^†
Operating profit margin	—	—	16.4%^†	12.7%^†	12.2%^†	4.6%^†	6.9%^†	4.6%^†	6.4%^†	3.9%^†	-18.0%^†	7.9%^†
Depreciation	—	—	14^†	13^†	13^†	12^†	11^†	10^†	10^†	10^†	10^†	10^†
Interest	—	—	30^†	37^†	29^†	21^†	21^†	23^†	33^†	40^†	31^†	21^†
Exceptional items, gain / (loss)	—	—	-4^†	0^†	0^†	-1^†	76^†	0^†	83^†	0^†	0^†	0^†
Profit before tax	—	—	60	30	31	-10	81^†	-12^†	65^†	-25^†	-32^†	-5^†
Tax	—	—	-6^†	—	0^†	0^†	-0^†	0^†	0^†	-0^†	-0^†	—
Net profit	—	—	66	31	30	-10	81^†	-13^†	64^†	-25^†	-32^†	-5^†
EPS	—	—	20.55^†	9.32^†	9.29^†	-3.00^†	25.29^†	-5.04^†	26.89^†	—	—	—

^† Derived: the sum of that fiscal year's four quarterly filings (a real annual filing is used wherever one exists). Checked against filed annual figures, the sum lands within 0.5% for about 94% of company-years.

Annual ratios (standalone)

Ratio	Mar 26	Mar 25	Mar 24	Mar 23	Mar 22	Mar 21	Mar 20	Mar 19	Mar 18	Mar 17
Operating margin	16.4%^†	12.7%^†	12.2%^†	4.6%^†	6.9%^†	4.6%^†	6.4%^†	3.9%^†	-18.0%^†	7.9%^†
EBIT margin	13.8%^†	11.1%^†	10.4%^†	2.2%^†	19.9%^†	2.7%^†	26.5%^†	3.8%^†	-0.4%^†	3.7%^†
PBT margin	9.2%	4.9%	5.3%	-2.1%	15.9%^†	-3.2%^†	17.6%^†	-6.4%^†	-8.7%^†	-1.1%^†
Net margin	10.2%	5.1%	5.3%	-2.1%	15.9%^†	-3.2%^†	17.5%^†	-6.3%^†	-8.5%^†	-1.2%^†
Interest coverage	3.00x^†	1.80x^†	2.05x^†	0.52x^†	4.94x^†	0.46x^†	2.97x^†	0.37x^†	-0.05x^†	0.78x^†
Dividend payout	0.0%^†	0.0%^†	0.0%^†	—	0.0%^†	—	0.0%^†	—	—	—
Earnings retention	100.0%^†	100.0%^†	100.0%^†	—	100.0%^†	—	100.0%^†	—	—	—
Current ratio	1.19x	1.11x	—	—	—	—	—	—	—	—
Quick ratio	0.93x	0.89x	—	—	—	—	—	—	—	—
Debt to equity	1.49x	2.92x	—	—	—	—	—	—	—	—
Return on equity	45.8%	51.5%	—	—	—	—	—	—	—	—
Return on assets	12.8%	7.4%	—	—	—	—	—	—	—	—
Return on capital employed	28.4%^†	27.8%^†	—	—	—	—	—	—	—	—
Asset turnover	1.26x	1.45x	—	—	—	—	—	—	—	—

Margins and asset turnover use operating revenue (interest earned for banks, excluding other income), not total income. Liquidity, leverage and return ratios need a filed standalone balance sheet, which exists only for recent years; returns use year-end equity/assets. Dividend payout is shown only for companies with a dividend record. † = built from a summed fiscal year.

Revenue Mix

Data unavailable.

Cash Flow

Year ended	Operating (₹ Cr)	Investing (₹ Cr)	Financing (₹ Cr)	Capex (₹ Cr)	Free Cash Flow (₹ Cr)
March 31, 2026	32	-56	22	59	-28
March 31, 2025	26	-51	26	49	-23
March 31, 2024	4	-17	15	0	4
March 31, 2023	20	-9	-32	0	20
March 31, 2022	38	1	-26	0	38

Balance Sheet (standalone)

Year ended	Total Assets (₹ Cr)	Total Equity (₹ Cr)	Reserves (₹ Cr)	Borrowings, Current (₹ Cr)	Borrowings, Non-current (₹ Cr)	Current Assets (₹ Cr)	Current Liabilities (₹ Cr)	Cash & Equivalents (₹ Cr)	Net Block (₹ Cr)	Inventory (₹ Cr)
March 31, 2026	518	144	110	68	147	239	201	2	227	51
March 31, 2025	414	59	27	13	160	193	175	4	190	38
March 31, 2024	—	—	—	—	—	—	—	—	—	—
March 31, 2023	—	—	—	—	—	—	—	—	—	—
March 31, 2022	—	—	—	—	—	—	—	—	—	—

Financial charts

Trend charts drawn from the standalone income-statement and ratio tables above (oldest year on the left); a gap means that period has no figure. Annual years marked † in the tables are derived from four quarters.